Phase 3 open-label 13-valent pneumococcal conjugate vaccine trial in healthy children partially immunized with Prevenar

Phase 3, open-label trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Wyeth. Primary endpoints: Serotype-specific IgG antibody concentration after the last scheduled dose, Pneumococcal immune response 1 month after infant dose in Group 1 and 1 more. Started Dec 2008; status: completed.